Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 3:15:1351675.
doi: 10.3389/fimmu.2024.1351675. eCollection 2024.

Scleroderma and scleroderma-like syndromes

Katarzyna Romanowska-Próchnicka  1 , Martyna Dziewit  1 , Aleksandra Lesiak  2 , Adam Reich  3 , Marzena Olesińska  1
Affiliations
Review

Scleroderma and scleroderma-like syndromes

Katarzyna Romanowska-Próchnicka et al. Front Immunol. .

Erratum in

  • Corrigendum: Scleroderma and Scleroderma-like syndromes.
    Romanowska-Próchnicka K, Dziewit M, Lesiak A, Reich A, Olesińska M. Romanowska-Próchnicka K, et al. Front Immunol. 2024 Jul 22;15:1456067. doi: 10.3389/fimmu.2024.1456067. eCollection 2024. Front Immunol. 2024. PMID: 39104532 Free PMC article.

Abstract

Systemic sclerosis is a systemic connective tissue disease whose main pathophysiological mechanism is a progressive fibrosis of internal organs and skin leading to thickening and induration. Blood vessels may also be involved. However, systemic scleroderma is not the only disease causing cutaneous sclerosis. There is a group of diseases that mimic scleroderma in their clinical presentation - these are scleroderma-like syndromes. A distinction can be made between syndromes of inflammatory/autoimmune, genetic, metabolic, toxic, drug-induced, occupational, paraneoplastic and syndromes caused by deposition disorders. In the following paper, we have reviewed the literature on scleroderma-like syndromes. We have outlined the factors predisposing to the development of each disease, its pathogenesis, clinical presentation, diagnostic and treatment process and the differences between each syndrome and systemic scleroderma.

Keywords: genetic; morphea; scleroderma; scleroderma-like syndromes; syndromes of inflammatory/autoimmune; systemic sclerosis; toxic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Scleroderma-like disorders.
Figure 2
Figure 2
Dominant areas of affected skin.
See this image and copyright information in PMC

References

    1. Allanore Y Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J. Systemic sclerosis. Nat Rev Dis Primers. (2015) 1:15002. doi: 10.1038/nrdp.2015.2 - DOI - PubMed
    1. Denton CP, Khanna D. Systemic sclerosis. Lancet. (2017) 390:1685–99. doi: 10.1016/s0140-6736(17)30933-9 - DOI - PubMed
    1. Adigun R, Goyal A, Hariz A. Systemic Sclerosis. In: StatPearls. StatPearls Publishing, Treasure Island (FL: (2022). - PubMed
    1. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. (2013) 65:2737–47. doi: 10.1002/art.38098 - DOI - PMC - PubMed
    1. Delgaldo F, Lescoat A, Conaghan PG, Ananyeva LP, Balbir-Gurman A, Bertoldo E, et al. . OP0234 2023 update of eular recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases. (2023) 82:154–5. doi: 10.1136/annrheumdis-2023-eular.1383 - DOI